Adaptive Biotechnologies (ADPT) Gains from Investment Securities (2018 - 2026)

Adaptive Biotechnologies has disclosed Gains from Investment Securities across 9 years of filings, most recently posting $1109.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $1109.0, up 101.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $1109.0 (down 99.94% YoY), and the FY2025 annual result was $10.0 million, down 18.31% from the prior year.
• Gains from Investment Securities came in at $1109.0 for Q1 2026 at Adaptive Biotechnologies, up from -$101000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $15.0 million in Q1 2022 to a low of -$114000.0 in Q1 2024.
• The 5-year median for Gains from Investment Securities is $1.6 million (2022), against an average of $5.3 million.
• Across the five-year window, Gains from Investment Securities surged 10885.51% in 2022 and plunged 192.44% in 2024, its largest moves.
• Adaptive Biotechnologies' Gains from Investment Securities stood at $7.6 million in 2022, then sank by 79.35% to $1.6 million in 2023, then plunged by 77.44% to $353000.0 in 2024, then plunged by 128.61% to -$101000.0 in 2025, then surged by 101.1% to $1109.0 in 2026.
• The last three Gains from Investment Securities figures came in at $1109.0 (Q1 2026), -$101000.0 (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.